OBJECTIVE: To explore the efficacy of allogeneic bone marrow transplantation (allo-BMT) for the treatment of Bruton disease. METHODS: HLA-matched sibling bone marrow transplantation was performed for the treatment of 2 cases of X-linked agammaglobulinemia. One of them received allo-BMT twice. RESULTS: Recovery of hematopoiesis was gained at day 20 and day 13 after allo-BMT in the two cases respectively. Serum immunoglobin rose gradually to normal level in three months. Their humoral immuno-system was reconstituted and life quality improved. These two patients are still in disease-free survival for 13 and 2 years respectively. There was no serious graft-versus-host-disease. CONCLUSION: Stem cell transplantation is a choice for the treatment of Bruton disease.
OBJECTIVE: To explore the efficacy of allogeneic bone marrow transplantation (allo-BMT) for the treatment of Bruton disease. METHODS: HLA-matched sibling bone marrow transplantation was performed for the treatment of 2 cases of X-linked agammaglobulinemia. One of them received allo-BMT twice. RESULTS: Recovery of hematopoiesis was gained at day 20 and day 13 after allo-BMT in the two cases respectively. Serum immunoglobin rose gradually to normal level in three months. Their humoral immuno-system was reconstituted and life quality improved. These two patients are still in disease-free survival for 13 and 2 years respectively. There was no serious graft-versus-host-disease. CONCLUSION: Stem cell transplantation is a choice for the treatment of Bruton disease.
Authors: Ben M J Shillitoe; Mark Ponsford; Mary A Slatter; Jennifer Evans; Siske Struik; Mike Cosgrove; Iolo Doull; Stephen Jolles; Andrew R Gennery Journal: J Clin Immunol Date: 2021-06-23 Impact factor: 8.317